Azithromycin 1.5% Ophthalmic SolutionIn Purulent Bacterial or Trachomatous Conjunctivitis

被引：0
|
作者：
Karly P. Garnock-Jones
机构：
[1] Adis,
来源：
Drugs | 2012年 / 72卷
关键词：
Azithromycin; Tobramycin; Conjunctivitis; Ophthalmic Solution; Clinical Cure Rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The second-generation macrolide azithromycin is available as a 1.5% ophthalmic solution for use in the treatment of bacterial or trachomatous conjunctivitis. This article reviews the pharmacological properties of azithromycin 1.5% ophthalmic solution and its clinical efficacy and tolerability in patients with purulent bacterial conjunctivitis or trachomatous conjunctivitis caused by Chlamydia trachomatis.
引用
收藏
页码：361 / 373
页数：12
相关论文
共 50 条
  • [31] Besifloxacin Ophthalmic Suspension, 0.6%: a Novel Topical Fluoroquinolone for Bacterial Conjunctivitis
    O'Brien, Terrence P.
    ADVANCES IN THERAPY, 2012, 29 (06) : 473 - 490
  • [32] Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis
    Cavet, Megan E.
    Gomes, Paul J.
    Carr, Warner W.
    Williams, Jon I.
    JOURNAL OF ASTHMA AND ALLERGY, 2018, 11 : 29 - 39
  • [33] Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
    Sanfilippo, Christine M.
    Allaire, Catherine M.
    DeCory, Heleen H.
    DRUGS IN R&D, 2017, 17 (01) : 167 - 175
  • [34] Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
    Christine M. Sanfilippo
    Catherine M. Allaire
    Heleen H. DeCory
    Drugs in R&D, 2017, 17 : 167 - 175
  • [35] Zymar - Gatifloxacin ophthalmic solution, 0.3% - Allergan - Fluoroquinolone approved for bacterial conjunctivitis
    不详
    FORMULARY, 2003, 38 (06) : 353 - 353
  • [36] Gatifloxacin Ophthalmic Solution for Treatment of Bacterial Conjunctivitis: Safety, Efficacy and Patient Perspective
    Schultz, Clyde
    OPHTHALMOLOGY AND EYE DISEASES, 2012, 4 : 65 - 70
  • [37] In Vitro Susceptibility to Different Topical Ophthalmic Antibiotics of Bacterial Isolates in Patients with Conjunctivitis
    Giardini, F.
    Vana, M.
    de Sanctis, U.
    Eandi, C.
    Machetta, F.
    Pollino, C.
    Grignolo, F. M.
    PROCEEDINGS OF THE 7TH INTERNATIONAL SYMPOSIUM ON OCULAR PHARMACOLOGY AND THERAPEUTICS, 2008, : 137 - +
  • [38] Besifloxacin Ophthalmic Suspension, 0.6% Compared with Gatifloxacin Ophthalmic Solution, 0.3% for the Treatment of Bacterial Conjunctivitis in Neonatal Patients
    Ong, Tuyen
    Allaire, Catherine
    Morris, Timothy W.
    Sforzolini, Baldo
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [39] Formulation and Development of Nanofiber-Based Ophthalmic Insert for the Treatment of Bacterial Conjunctivitis
    Farkas, Eszter
    Abboud, Houssam
    Nagy, Nandor
    Hofmeister, Balint
    Ostorhazi, Eszter
    Toth, Bence
    Pinke, Balazs
    Meszaros, Laszlo
    Zelko, Romana
    Kazsoki, Adrienn
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (17)
  • [40] Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis
    Khimdas, S.
    Visscher, K. L.
    Hutnik, C. M. L.
    OPHTHALMOLOGY AND EYE DISEASES, 2011, 3
12345